Tag: Alzheimer’s disease

Physicians Educational Resource

Physicians’ Education Resource releases agenda for the 1st Annual International Congress...

Physicians’ Education Resource (PER), a worldwide leading resource for continuing medical education (CME), announces the full agenda for the 1st Annual International Congress on...

Deep brain stimulation showing promise for patients with mild Alzheimer’s disease...

An age group analysis of data from the ADvance trial has shown that participants over the age of 65 continue to derive the most...

Fujifilm’s T-817MA Alzheimer’s drug fails to meet primary study endpoints

Fujifilm’s T-817MA drug has not met its primary study endpoints of cognition or global clinical function in its US Phase II clinical trial conducted...

Regional shortage of neurologists revealed across the USA

According to new data reported at the 2017 Alzheimer's Association International Conference (AAIC 2017, London, UK), multiple regions of the United States have been...

First Alzheimer’s trial with focused ultrasound begins

Researchers at Sunnybrook Health Sciences Centre in Toronto, Canada have begun the world’s first clinical trial evaluating the feasibility and safety of opening the...

Findings support role of vascular disease in development of Alzheimer’s disease

Among adults who entered a study more than 25 years ago, an increasing number of midlife vascular risk factors, such as obesity, high blood...

Hormone therapy may not protect against Alzheimer’s disease

The latest study on hormone therapy and Alzheimer’s disease shows no relationship between taking the drugs and developing the disease years later. Some previous...

First large, placebo-controlled double-blind stody of rTMS for Alzheimer’s receives funding

Funding for clinical trials of a new treatment for Alzheimer’s disease has been announced by the Weston Brain Institute, Toronto, Canada. Zahra Moussavi, Canada...

Neuronix submits neuroAD System for FDA clearance

Neuronix has announced positive results from its pivotal, double-blind placebo-controlled, multicentre clinical study, for the assessment of safety and efficacy of the neuroAD Therapy...